Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Paradigm4 has signed an agreement with 54Gene allowing the latter to use the former’s Reveal Biobank App to explore, characterise and query 54Gene’s African Health Information Ecosystem, which is a curated data source of clinical phenotype and genetic information from which insights can be generated to assist the development of
Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns